Across TCGA pan-cancer cohorts, LCE3A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LCE3A data layer compared with 14 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LCE3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LCE3A expression acts as an unfavorable survival marker.

BLCA, LGG, and UCEC are the cancer types where LCE3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.141	0.655	.002	27	view →
LGG	DFS	Median	All	0.225	0.738	.014	6	view →
UCEC	DFS	Median	All	0.543	0.839	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LCE3A tumor-vs-normal RNA expression · all LCE3A data types